Ultragenyx Pharmaceutical Financial Overview
Ultragenyx Pharmaceutical's market cap is currently $3.31B. The company's EPS TTM is $-1.81; its P/E ratio is -5.59; Ultragenyx Pharmaceutical is scheduled to report earnings on November 4, 2025, and the estimated EPS forecast is $-1.17. See an overview of income statement, balance sheet, and cash flow financials.
